{
    "root": "2f8911a1-ac9b-6c6c-e063-6394a90a7ac5",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Levofloxacin",
    "value": "20250304",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "POVIDONE",
            "code": "FZ989GH94E",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11061"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "LEVOFLOXACIN",
            "code": "6GNT3Y5LMF",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63598"
        }
    ],
    "indications": {
        "text": "levofloxacin fluoroquinolone antibacterial indicated adults ( 18 years age older ) infections caused designated , susceptible bacteria pediatric patients indicated ( 1 , 12.4 ) . \u2022 pneumonia : nosocomial ( 1.1 ) community acquired ( 1.2 , 1.3 ) \u2022 skin skin structure infections ( sssi ) : complicated ( 1.4 ) uncomplicated ( 1.5 ) \u2022 chronic bacterial prostatitis ( 1.6 ) \u2022 inhalational anthrax , post-exposure adult pediatric patients ( 1.7 ) \u2022 plague adult pediatric patients ( 1.8 ) \u2022 urinary tract infections ( uti ) : complicated ( 1.9 , 1.10 ) uncomplicated ( 1.12 ) \u2022 acute pyelonephritis ( 1.11 ) \u2022 acute bacterial exacerbation chronic bronchitis ( 1.13 ) \u2022 acute bacterial sinusitis ( 1.14 ) usage reduce development drug-resistant bacteria maintain effectiveness levofloxacin antibacterial drugs , levofloxacin used treat prevent infections proven strongly suspected caused bacteria ( 1.15 ) .",
        "doid_entities": [
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "prostatitis (DOID:14654)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14654"
            },
            {
                "text": "plague (DOID:3482)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3482"
            },
            {
                "text": "uti (DOID:0080784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080784"
            },
            {
                "text": "acute pyelonephritis (DOID:559)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_559"
            },
            {
                "text": "pyelonephritis (DOID:11400)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11400"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "sinusitis (DOID:0050127)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050127"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic bacterial prostatitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_330064"
            },
            {
                "disease": "acute bacterial sinusitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_206994"
            }
        ]
    },
    "contraindications": {
        "text": "\u2022 administer levofloxacin tablets pediatric patients weighing 30 kg greater ( 2.1 , 2.2 ) . \u2022 levofloxacin tablets administered pediatric patients weigh less 30 kg limitations available strengths . alternative formulations levofloxacin may considered pediatric patients weigh less 30 kg ( 2.2 ) . adult pediatric patients creatinine clearance greater equal 50 ml/minute ( 2.1 . 2.2 ) type infection dose every 24 hours duration ( days ) nosocomial pneumonia ( 1.1 ) 750 mg 7 14 community acquired pneumonia ( 1.2 ) 500 mg 7 14 community acquired pneumonia ( 1.3 ) 750 mg 5 complicated sssi ( 1.4 ) 750 mg 7 14 uncomplicated sssi ( 1.5 ) 500 mg 7 10 chronic bacterial prostatitis ( 1.6 ) 500 mg 28 inhalational anthrax ( post-exposure ) ( 1.7 ) adults pediatric patients 50 kg greater pediatric patients 30 kg less 50 kg ( 2.2 ) 500 mg 250 mg every 12 hours 60 60 plague ( 1.8 ) adults pediatric patients 50 kg greater pediatric patients 30 kg less 50 kg ( 2.2 ) 500 mg 250 mg every 12 hours 10 14 10 14 complicated uti ( 1.9 ) acute pyelonephritis ( 1.11 ) 750 mg 5 complicated uti ( 1.10 ) acute pyelonephritis ( 1.11 ) 250 mg 10 uncomplicated uti ( 1.12 ) 250 mg 3 acute bacterial exacerbation chronic bronchitis ( 1.13 ) 500 mg 7 acute bacterial sinusitis ( 1.14 ) 750 mg 5 500 mg 10 14 \u2022 adjust dose creatinine clearance less 50 ml/minute ( 2.3 , 8.6 , 12.3 )",
        "doid_entities": [
            {
                "text": "pneumonia (DOID:552)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_552"
            },
            {
                "text": "prostatitis (DOID:14654)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_14654"
            },
            {
                "text": "plague (DOID:3482)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3482"
            },
            {
                "text": "uti (DOID:0080784)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0080784"
            },
            {
                "text": "acute pyelonephritis (DOID:559)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_559"
            },
            {
                "text": "pyelonephritis (DOID:11400)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_11400"
            },
            {
                "text": "chronic bronchitis (DOID:6132)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6132"
            },
            {
                "text": "sinusitis (DOID:0050127)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050127"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "chronic bacterial prostatitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_330064"
            },
            {
                "disease": "acute bacterial sinusitis",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_206994"
            }
        ]
    },
    "warningsAndPrecautions": "\u2022levofloxacin tablets usp , 500 mg orange colored , capsule shaped , biconvex , film coated tablets debossed '26 ' one side ' ' side . supplied bottles 50 tablets ndc 68071-3511-5 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "levofloxacin tablets contraindicated persons known hypersensitivity levofloxacin , quinolone antibacterials [ ( 5.3 ) ] .",
    "indications_original": "Levofloxacin is a fluoroquinolone antibacterial indicated in adults (18 years of age and older) with infections caused by designated, susceptible bacteria and in pediatric patients where indicated\u00a0 (1, 12.4). \u2022\u00a0Pneumonia: Nosocomial (1.1) and Community Acquired (1.2, 1.3) \u2022\u00a0Skin and Skin Structure Infections (SSSI): Complicated (1.4) and Uncomplicated (1.5) \u2022\u00a0Chronic bacterial prostatitis (1.6) \u2022\u00a0Inhalational Anthrax, Post-Exposure\u00a0 in adult and pediatric patients\u00a0 (1.7) \u2022\u00a0Plague in adult and pediatric patients (1.8) \u2022\u00a0Urinary Tract Infections (UTI): Complicated (1.9, 1.10) and Uncomplicated (1.12) \u2022\u00a0Acute Pyelonephritis (1.11) \u2022\u00a0Acute Bacterial Exacerbation of Chronic Bronchitis (1.13) \u2022\u00a0Acute Bacterial Sinusitis (1.14) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria (1.15).",
    "contraindications_original": "\u2022\u00a0Administer Levofloxacin Tablets to pediatric patients\u00a0 weighing 30 kg and greater\u00a0 only (2.1, 2.2). \u2022\u00a0Levofloxacin Tablets cannot be administered to pediatric patients who weigh less than 30 kg because of the limitations of the available strengths. Alternative formulations of levofloxacin may be considered for pediatric patients who weigh less than 30 kg (2.2). Dosage in Adult and Pediatric Patients with Creatinine Clearance greater than or equal to 50 mL/minute (2.1. 2.2) Type of Infection Dose Every 24 hours Duration (days) Nosocomial Pneumonia (1.1) 750 mg 7 to 14 Community Acquired Pneumonia (1.2) 500 mg 7 to 14 Community Acquired Pneumonia (1.3) 750 mg 5 Complicated SSSI (1.4) 750 mg 7 to 14 Uncomplicated SSSI (1.5) 500 mg 7 to 10 Chronic Bacterial Prostatitis (1.6) 500 mg 28 Inhalational Anthrax (Post-Exposure) (1.7) Adults and Pediatric Patients 50 kg or greater Pediatric Patients 30 kg to less than 50 kg (2.2) 500 mg 250 mg every 12 hours 60 60 Plague (1.8) Adults and Pediatric Patients 50 kg or greater Pediatric Patients 30 kg to less than 50 kg (2.2) 500 mg 250 mg every 12 hours 10 to 14 10 to 14 Complicated UTI (1.9) or Acute Pyelonephritis (1.11) 750 mg 5 Complicated UTI (1.10) or Acute Pyelonephritis (1.11) 250 mg 10 Uncomplicated UTI (1.12) 250 mg 3 Acute Bacterial Exacerbation of Chronic Bronchitis (1.13) 500 mg 7 Acute Bacterial Sinusitis (1.14) 750 mg 5 500 mg 10 to 14 \u2022\u00a0 Adjust dose for creatinine clearance less than 50 mL/minute (2.3, 8.6, 12.3)",
    "warningsAndPrecautions_original": "\u2022Levofloxacin Tablets USP, 500 mg are orange colored, capsule shaped, biconvex, film coated tablets debossed with '26' on one side and 'I' on the other side. They are supplied in\n  \n   Bottles of 50 tablets                                               NDC 68071-3511-5\n  \n                     \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Levofloxacin tablets are contraindicated in persons with known hypersensitivity to levofloxacin, or other quinolone antibacterials\n \n  [see Warnings and Precautions (\n  \n   5.3)].",
    "drug": [
        {
            "name": "Levofloxacin",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63598"
        }
    ]
}